AngioDynamics (FRA:UG2) EBIT: €-17.6 Mil (TTM As of Feb. 2026)


FRA:UG2 AngioDynamics Inc FRA:UG2
62 GF Score
Price €10.80
GF Value €7.27
! 7 Warning Signs
View Full Analysis

What is AngioDynamics EBIT?

AngioDynamics FRA:UG2 -0.92% 62 EBIT is €-17.6 Mil as of Feb. 2026. GuruFocus rates FRA:UG2 with a GF Score™ of 62/100 and a GF Value™ of €7.27. The stock has 7 warning signs investors should review.

AngioDynamics's earnings before interest and taxes (EBIT) for the three months ended in Feb. 2026 was €-5.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Feb. 2026 was €-17.6 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. AngioDynamics's annualized ROC % for the quarter that ended in Feb. 2026 was -15.52%. AngioDynamics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was -31.98%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. AngioDynamics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Feb. 2026 was -4.27%.


AngioDynamics  (FRA:UG2) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

AngioDynamics's annualized ROC % for the quarter that ended in Feb. 2026 is calculated as:

ROC % (Q: Feb. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Nov. 2025 ) + Invested Capital (Q: Feb. 2026 ))/ count )
=-21.756 * ( 1 - 0% )/( (142.196 + 138.125)/ 2 )
=-21.756/140.1605
=-15.52 %

where

Note: The Operating Income data used here is four times the quarterly (Feb. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

AngioDynamics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Feb. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Feb. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Nov. 2025  Q: Feb. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-21.756/( ( (26.406 + max(41.302, 0)) + (24.654 + max(43.718, 0)) )/ 2 )
=-21.756/( ( 67.708 + 68.372 )/ 2 )
=-21.756/68.04
=-31.98 %

where Working Capital is:

Working Capital(Q: Nov. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(38.435 + 56.717 + 8.398) - (55.061 + 0.24 + 6.947)
=41.302

Working Capital(Q: Feb. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(38.537 + 49.557 + 11.516) - (50.422 + 0.239 + 5.231)
=43.718

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Feb. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

AngioDynamics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Feb. 2026 )
=-17.599/412.511
=-4.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AngioDynamics EBIT Related Terms


AngioDynamics EBIT Historical Data

* Premium members only.

The historical data trend for AngioDynamics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AngioDynamics EBIT Chart

AngioDynamics Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.96 -17.23 -17.19 -31.31 -21.34

AngioDynamics Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -6.38 -3.22 -6.78 -2.15 -5.44

FRA:UG2 vs OSUR, UTMD, SMTI: EBIT Comparison

For the Medical Instruments & Supplies subindustry, AngioDynamics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AngioDynamics EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, AngioDynamics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AngioDynamics's EV-to-EBIT falls into.


FRA:UG2
62GF Score
AngioDynamics Inc FRA:UG2
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AngioDynamics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Feb. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-17.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €-17.6 Mil mean?
AngioDynamics (FRA:UG2) has a EBIT of €-17.6 Mil as of Feb. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on AngioDynamics.
Is AngioDynamics' EBIT too high?
AngioDynamics' current EBIT is €-17.6 Mil. Overall, AngioDynamics has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does AngioDynamics' EBIT compare to OSUR and UTMD?
AngioDynamics' EBIT of €-17.6 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on AngioDynamics. AngioDynamics's current EBIT is €-17.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AngioDynamics stock overvalued right now?
AngioDynamics (FRA:UG2) has a current EBIT of €-17.6 Mil. The stock's GF Value™ is €7.27, compared to a current price of €10.80 — trading 48.6% above its estimated fair value. The current EBIT is €-17.6 Mil. AngioDynamics' overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For AngioDynamics (FRA:UG2), the current EBIT is €-17.6 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AngioDynamics (FRA:UG2) Overvalued in 2026?

Based on GuruFocus' analysis, AngioDynamics stock appears to be overvalued. The current stock price of €10.80 is trading 48.6% above its estimated GF Value™ of €7.27.

Key valuation signals for FRA:UG2:

  • EBIT: €-17.6 Mil
  • GF Value™: €7.27 vs. price of €10.80 (48.6% above fair value)
  • GF Score™: 62/100 with 7 warning signs

No single metric tells the full story. See the FRA:UG2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AngioDynamics Business Description

Other Exchanges ANGO:USA
Address 14 Plaza Drive, Latham, NY, USA, 12110
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
62GF Score

Get the complete analysis for FRA:UG2

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.80
Price
€7.27
GF Value